Lupus erythematosus
☆ Liphethong tsa 2022 Stiftung Warentest tse tsoang Jeremane, khotsofalo ea bareki ka ModelDerm e ne e le tlase hanyane ho feta lipuisano tse lefelloang tsa telemedicine.
E bonahala e le erythema e pherese hanyane.
Lekhopho la serurubele leo hangata le hlahang sefahlehong.
References
Ho hlwaya le ho arola cutaneous lupus erythematosus (CLE) ho hlahisa mathata a tlhahlobo, ho e khetholla ho systemic lupus erythematosus ka ho kenya letsoho letlalong. Lithuto tsa morao-rao li fana ka leseli mabapi le liphatsa tsa lefutso, tsa tikoloho le tsa immunology tse thehileng CLE. Ho kenngoa ha lithethefatsi ka ho khetheha ho hlahile e le e 'ngoe ea lintho tse susumetsang CLE. Kalafo e kenyelletsa liphekolo tsa lihlooho le tsa tsamaiso, ho kenyeletsoa le litlhare tse tšepisang (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , tse nang le katleho e bonts'itsoeng litekong tsa bongaka.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) e akaretsa litaba tse fapaneng tsa letlalo, tse ling tsa tsona li ka amahanngoa le mathata a bophelo bo botle. E arotsoe ka mefuta e fapaneng, joalo ka acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE e na le discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus ke sehlopha sa mafu a autoimmune a ka amang likarolo tse fapaneng tsa 'mele. Mefuta e meng, joalo ka systemic lupus erythematosus (SLE) , e ama litho tse ngata, ha tse ling, joalo ka cutaneous lupus erythematosus (CLE) , li ama letlalo haholo. Re arola mefuta e fapaneng ea CLE ho ipapisitse le motsoako oa matšoao a bongaka, tlhahlobo ea lisele le liteko tsa mali, empa ho na le phapang e ngata lipakeng tsa batho ka bomong. Hangata mathata a letlalo a hlaha ka lebaka la maemo a kang ho pepesehela khanya ea letsatsi, ho tsuba, kapa meriana e itseng.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Sesosa sa lupus erythematosus ha se hlake. Har'a mafahla a tšoanang, haeba le leng le ameha ho na le monyetla oa 24% hore le e mong le eena a be teng. Ho lumeloa hore lihomone tsa basali tsa thobalano, khanya ea letsatsi, ho tsuba, khaello ea vithamine D le mafu a itseng a eketsa kotsi.
Kalafo e ka kenyelletsa li-NSAID, corticosteroids, immunosuppressants, hydroxychloroquine, le methotrexate. Le hoja corticosteroids e sebetsa, tšebeliso ea nako e telele e baka litla-morao.